JK07 for Heart Failure

"As this is a Phase 1 trial, there are only preliminary studies which have been conducted to assess JK07's safety; thus our assessment of its risk was rated as low on a scale from 1 to 3."

"This medical trial is specifically looking for participants aged 18 to 85 years old. Subsequent studies will be conducted on those younger than 18 and older than 65, totalling 713 trials in total."

"Patients can currently join this clinical trial at 8 different locations, including Rochester, Saint Louis and Stanford. It is important to select the most convenient site for you to minimize travel time if accepted into the study."

"This clinical trial is seeking 56 participants aged between 18 and 85 with a diagnosis of chronic heart failure. To be eligible, they should display the following characteristics: Stable NYHA class II or III HF symptoms evident for at least half a year, elevated LV end-diastolic pressure/pulmonary capillary wedge pressure (15 mm Hg+ resting; 25 mm HG + exercising), high NT-proBNP & BNP levels (>400 pg/mL & >200 pg/mL respectively), E/e' ratio ≥ 15 on echocardiogram & LAV above 58 mL (males) / 52"

"The trial necessitates 56 volunteers that meet the established criteria. Patients can partake in this study at either Mayo Clinic of Rochester, Minnesota and Washington University in Saint Louis, Missouri."

"Indeed, the information on clinicaltrials.gov states that this study is currently recruiting for 56 participants from 8 medical sites. The trial originally began recruitment efforts on October 21st 2022 and was most recently updated on November 3rd 2022."